arGEN-X SE

argenx SE, a commercial‑stage biopharma focused on antibody‑based therapies for autoimmune diseases, markets VYGART for myasthenia gravis and ITP, and develops a robust pipeline including efgartigimod and ARGX‑119, supported by strategic collaborations worldwide.

Headquarters: Belgium (BEL)

Website: Visit Site 🔗
Type: Corporation

Company Profile

Sector: Hospitals and Health Care
Industry: Medical Practices

Employees: 1,599
HQ: Amsterdam

Unlock the full potential.

Get access to Relative P/E Ratio Valuation Histogram.

Upgrade

Traded Instruments

+ Add Instrument 1

Symbol	Name	Type	Exchange	Currency	ISIN	Status	Actions
ARGX	arGEN-X SE Cap: 41.5B \| P/E: 33.4	EQUITY	BRU	EUR	NL0010832176	Active	📈